• PreScission Protease: Mechanistic Precision in Translational

  2026-07-13

  Explore how PreScission Protease (PSP) leverages HRV 3C protease specificity to enable precise fusion protein tag cleavage, fueling breakthroughs in chromatin and nuclear architecture research. This thought-leadership article integrates mechanistic insights, translational relevance, and strategic protocol guidance for researchers navigating complex protein purification challenges.

• CUDC-907: Practical Guide for Dual PI3K and HDAC Inhibition

  2026-07-13

  CUDC-907 is a dual PI3K and HDAC inhibitor designed for precise control of cell signaling, acetylation, and cell cycle pathways in in vitro oncology models. It should be used only in research workflows, not in diagnostic or medical contexts, and requires careful handling and protocol adherence for reproducible results.

• Hexetidine (NSC-17764): Rethinking Oral Biofilm & Antimicrob

  2026-07-12

  This thought-leadership article explores Hexetidine (NSC-17764) as a paradigm-shifting solution for oral antimicrobial research, integrating mechanistic insight, rigorous experimental validation, and translational strategic guidance. Drawing on pivotal biofilm-resistance literature and contemporary workflow best practices, the article highlights how APExBIO’s Hexetidine enables robust assay design, advances clinical relevance, and redefines the path forward for next-generation oral infection therapeutics.

• Ribociclib Succinate in Cell Cycle Regulation: Novel Assay S

  2026-07-10

  Explore how Ribociclib succinate (LEE011 succinate), a selective CDK inhibitor, advances the precision and reproducibility of cancer research assays. This article uniquely addresses practical solubility, protocol optimization, and biomarker integration for next-generation cell cycle studies.

• Diterpene JXE-23 Induces Autophagy and Arrests HCC Cell Grow

  2026-07-09

  The referenced study characterizes ent-8(14),15-pimaradiene-2β,19-diol (JXE-23) from Aleuritopteris albofusca as a selective inhibitor of hepatocellular carcinoma (HCC) cell growth. JXE-23’s mechanism involves G2/M cell cycle arrest and induction of protective autophagy, offering a new lead for anticancer drug discovery and insights into autophagy modulation strategies.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-07-09

  Schwartz's dissertation establishes a nuanced framework for evaluating anticancer drug responses in vitro by distinguishing proliferative arrest from cell death. This methodological advance enhances the interpretability and translational value of apoptosis-targeting agents, guiding more predictive drug development.

• Applied Azilsartan Medoxomil Monopotassium: From Bench to Mo

  2026-07-08

  Azilsartan medoxomil monopotassium (TAK 491) sets a new benchmark for high-affinity AT1 receptor antagonism, enabling robust, reproducible hypertension and cardiovascular disease research. This article unpacks experimental workflows, protocol refinements, and troubleshooting strategies with data-driven insights that maximize success with this APExBIO flagship compound.

• Reliable Cell Assays with (-)-Epinephrine (+)-bitartrate (B1

  2026-07-08

  This article offers a scenario-driven, evidence-backed guide to optimizing cell viability, proliferation, and cytotoxicity assays using (-)-Epinephrine (+)-bitartrate (SKU B1358). It addresses common laboratory challenges—such as reproducibility, protocol optimization, and product selection—by synthesizing validated literature and best practices, while highlighting how this non-selective adrenergic receptor agonist from APExBIO enables sensitive and robust experimental outcomes.

• Tivozanib (AV-951): Next-Generation VEGFR Inhibition in Onco

  2026-07-07

  Discover how Tivozanib (AV-951) redefines anti-angiogenic therapy in oncology research through unrivaled VEGFR selectivity and novel in vitro response metrics. Explore actionable, evidence-driven insights and protocol guidance for advanced cancer assays.

• miR-146a/b-5p–IRAK1–NF-κB Axis in Recurrent Spontaneous Abor

  2026-07-07

  This study uncovers a regulatory pathway involving miR-146a/b-5p, IRAK1, and the NF-κB signaling axis in unexplained recurrent spontaneous abortion (URSA). By integrating transcriptomic network analyses with functional assays, the authors demonstrate that miR-146a/b-5p modulates trophoblast function and inflammation by targeting IRAK1, offering a mechanistic basis for potential therapeutic intervention.

• Induced Bleb Structures Enhance LNP mRNA Transfection Potenc

  2026-07-06

  The referenced study demonstrates that the induction of 'bleb' structures in lipid nanoparticle (LNP) mRNA formulations—achieved through high-concentration pH 4 buffer—markedly improves transfection efficiency both in vitro and in vivo. This finding offers a formulation-based route to enhance mRNA delivery, emphasizing the significance of mRNA integrity and structural optimization in LNP design.

• E-64d: Applied Calpain Inhibition for Apoptosis and Neuropro

  2026-07-06

  E-64d enables precise, membrane-permeable inhibition of cysteine proteases—unlocking advanced workflows for dissecting apoptosis, platelet function, and neuroprotection. This guide details optimized protocols, troubleshooting insights, and the translational impact of E-64d, leveraging recent advances in death-rate analysis and regulated cell death research.

• Angiotensin I: Unraveling Mechanisms and Driving Translation

  2026-07-05

  Explore the mechanistic and translational landscape of Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu), its pivotal role in renin-angiotensin system research, and strategic guidance for leveraging this decapeptide in preclinical workflows, with insights into experimental rigor, protocol optimization, and future directions in cardiovascular and neuroendocrine modeling.

• Dacomitinib (PF-00299804): Pan-HER Inhibition and Ferroptosi

  2026-07-04

  Explore how Dacomitinib (PF-00299804) advances cancer research through potent pan-HER inhibition while intersecting with emerging insights into mitochondrial ferroptosis regulation. This article provides a deep, comparative analysis and practical guidance for translational oncology studies.

• SR-202: Advancing PPARγ Antagonism in Insulin Resistance Res

  2026-07-03

  SR-202, a highly selective PPARγ antagonist, empowers researchers to dissect the molecular basis of insulin resistance, adipogenesis, and immune-metabolic signaling with exceptional specificity. This article details best practices for applying SR-202 in experimental workflows, highlights troubleshooting strategies, and bridges recent advances in macrophage polarization and metabolic disease modeling.

16195 records 1/1080 page Next 12345 下5页 Last page